AcroMeta to Enter Ambient Temperature Cellular Logistics Through Strategic Partnership with Macro HRD
核心洞察
AcroMeta Group Limited (搜索) has entered a non-binding term sheet with Macro HRD SG Pte. Ltd. (搜索) to acquire a strategic stake in Macro-ATCLS Pte. Ltd. (搜索), the vehicle commercialising Ambient Temperature Cellular Logistics (ATCLS) technology.
The partnership grants AcroMeta an option to secure an exclusive licence to deploy the ATCLS platform across Southeast Asia, including the right to appoint sub-licensees.
ATCLS uses proprietary ambient-temperature preservation and reactivation technologies to transport dormant living cells without conventional refrigerated or cryogenic cold chains, supported by a Gradient Equilibrium Decision Modeling (GEDM) platform.
AcroMeta Group Limited (搜索) ("AcroMeta"), a Singapore Exchange Catalist-listed facility management services company, has announced a non-binding term sheet ("Term Sheet") with Macro HRD SG Pte. Ltd. (搜索) ("Macro"), a Singapore-based provider of management consultancy services to the healthcare sector. The Term Sheet sets out the principal terms for a strategic partnership between AcroMeta and Macro-ATCLS Pte. Ltd. (搜索) ("Macro-ATCLS"), the company through which Macro's Ambient Temperature Cellular Logistics technology is being commercialised.
Mr Lawrence Toh, Executive Director of AcroMeta Group Limited (搜索), said, "This proposed strategic partnership gives us the opportunity to build a position in an industry where cell and gene therapy logistics are expected to grow at double-digit rates in the years ahead. We see this as a natural extension of our strategy to grow our portfolio beyond our core operations, and we're excited about the potential to build a meaningful presence in bringing this technology into Southeast Asia."
Ambient Temperature Cellular Logistics (ATCLS)
Ambient Temperature Cell Logistics (ATCLS) is an emerging technology licensed by Macro HRD, designed to fundamentally transform the transportation and distribution of living cells and other temperature-sensitive biological materials by eliminating reliance on conventional refrigerated and cryogenic cold chains. ATCLS uses proprietary ambient-temperature preservation and reactivation technologies, supported by its proprietary Gradient Equilibrium Decision Modeling (GEDM) platform for real-time governance, chain-of-identity and process control, enabling dormant living cells to be transported at ambient temperature and reactivated at the point of use.
The opportunity addresses rapidly expanding markets including stem cells, CAR-T/immune-cell therapy, gene therapy, regenerative medicine, organ and tissue transplantation, and cell-and-gene-therapy logistics. The underlying markets cited in the project materials range from US$5.2 billion for immune-cell therapy to US$47 billion for organ transplantation, while the global cell-and-gene-therapy 3PL market is estimated at US$1.81 billion in 2025 and projected to reach US$16.95 billion by 2035 (25.1% CAGR).
Based on defined ambient-addressable segments, ATCLS estimates a Serviceable Addressable Market (SAM) of approximately US$14.5 billion by 2032, positioning the technology as a potential category-creating solution capable of reducing the cost, fragility and geographic limitations of conventional cold-chain logistics.
Proposed Exclusive Licensing Arrangement for Southeast Asia
AcroMeta will have an option to acquire an exclusive licence to deploy the ATCLS technology across agreed territories in Southeast Asia, including the right to appoint sub-licensees. The proposed exclusive licensing arrangement is intended to provide AcroMeta with the rights to develop and commercialise the ATCLS business within Southeast Asia.
This structure allows AcroMeta to secure exclusive rights across the Southeast Asian markets, together with a first right to acquire additional territories, significantly expanding the Group's potential commercial reach for the ATCLS technology.
Building AcroMeta's Platform Growth Strategy
The Group intends to continue evaluating strategic opportunities to support its long-term value creation for shareholders. The Board remains focused on disciplined capital allocation as the Group progresses through its next phase of development.
About the Partners
AcroMeta Group Limited (搜索) (SGX: 43F) is in the business of facility management services and has been listed on the Catalist board of the Singapore Exchange since 2016. Macro HRD SG Pte. Ltd. (搜索) is a Singapore-based biotechnology and therapeutics company established in 2024, focused on developing scalable, precision-medicine solutions for high-burden infectious diseases with significant unmet medical needs. Macro HRD integrates advanced biology, therapeutic platform technologies and AI/ML-enabled decision systems to accelerate drug discovery and translational development, with a development portfolio targeting HIV/AIDS (搜索), HPV (搜索) and other enveloped viruses.
The market data cited in the project materials was provided by Macro's management and has not been verified by the board of directors, which have not audited or verified the data supplied by the company.